부산대학교 도서관

The Tema Cardiovascular and Metabolic ETF (HRTS) is a new biotechnology exchange-traded fund that focuses on companies involved in the treatment of cardio-metabolic diseases, including cardiovascular diseases, obesity, and diabetes. The fund charges a 0.75% management fee and has 20 to 25 core positions, including companies like Eli Lilly & Co., Novo Nordisk A/S, Arrowhead Pharmaceuticals Inc., and Bridgebio Pharma Inc. The launch of this ETF coincides with increased interest in obesity drugs, such as Novo's Ozempic and Wegovy, as well as Eli Lilly's Mounjaro and Zepbound. The fund aims to invest in structural trends rather than short-term momentum trades. Despite competition from other biotechnology ETFs, Tema's research-driven approach and use of a specialist portfolio manager set it apart. Thematic ETFs have seen outflows of $4.7 billion this year, compared to $2.4 billion last year. Tema plans to launch a neurology-focused ETF in early 2024. [Extracted from the article]